Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00255)
Name	Ethotoin
Synonyms	Click to Show/Hide the Synonyms of This API ethotoin; Peganone; 86-35-1; 3-Ethyl-5-phenylhydantoin; 3-ethyl-5-phenylimidazolidine-2,4-dione; Ethotoine; Ethotoinum; Etotoina; Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; 2,4-Imidazolidinedione, 3-ethyl-5-phenyl-; Hydantoin, 3-ethyl-5-phenyl-; (+-)-3-Ethyl-5-phenylhydantoin; 3-ethyl-5-phenyl-imidazolidine-2,4-dione; AC-695; Accenon; CHEBI:4888; Accenon; Pegoanone; Peganone (TN); Accenon (TN); HSDB 3580; EINECS 201-665-1; Ethotoin (JAN/USP/INN); BRN 0188272; Ethotoin [USP:INN:BAN:JAN]; CAS-86-35-1; NCGC00016340-01; (.+/-.)-Ethotoin; Prestwick0_000696; Prestwick1_000696; Prestwick2_000696; Prestwick3_000696; DSSTox_CID_3020; CHEMBL1095; DSSTox_RID_76833; DSSTox_GSID_23020; Oprea1_374844; SCHEMBL34301; BSPBio_000851; 5-24-08-00005 (Beilstein Handbook Reference); MLS002153961; SPBio_002772; ETHOTOIN (200 MG); 2,4-Imidazolidinedione, 3-ethyl-5-phenyl-, (+-)-; BPBio1_000937; GTPL7183; DTXSID6023020; HMS1570K13; HMS2097K13; HMS2232M06; HMS3371O03; HMS3714K13; HMS3887I05; Pharmakon1600-01505428; (+/-)-3-ethyl-5-phenylhydantoin; Tox21_110383; MFCD00072127; NSC760074; AKOS008947805; CCG-213433; DB00754; MCULE-6544505383; NSC-760074; NCGC00179401-01; NCGC00179401-03; NS-02146; SMR001233300; 3-Ethyl-5-phenyl-2,4-imidazolidinedione #; AB00513897; C07839; D00708; AB00513897_07; SR-01000841832; Q4533122; SR-01000841832-2; Z53845223; 1-ethyl-2-hydroxy-4-phenyl-4,5-dihydro-1H-imidazol-5-one
Clinical Status	Approved
Disease Indication	Focal seizure		ICD-11: 8A68	[1]
PubChem CID	3292
Formula	C11H12N2O2
Canonical SMILES	CCN1C(=O)C(NC1=O)C2=CC=CC=C2
InChI	1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
InChIKey	SZQIFWWUIBRPBZ-UHFFFAOYSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3292"></iframe>
Structure	3D MOL		2D MOL
Physicochemical Properties	Molecular Weight	204.22	Topological Polar Surface Area	49.4
	XlogP	1	Complexity	272
	Heavy Atom Count	15	Rotatable Bond Count	2
	Hydrogen Bond Donor Count	1	Hydrogen Bond Acceptor Count	2

Full List of Drug Formulations (DFMs) Containing This API
Ethotoin 250 mg tablet			Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Stearic acid; Lactose; Talc; Carboxymethylcellulose sodium; Acacia
Dosage Form	Oral Tablet
Company	Lundbeck Pharmaceuticals
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Stearic acid	DIG Info	Phosphodiesterase 3A (IC50 = 3.1 uM)	[2]
	Carboxymethylcellulose sodium	DIG Info	Albendazole monooxygenase (EC50 = 12.6 uM)	[3]
Drug Formulation 2	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Stearic acid; Lactose, unspecified form; Talc; Acacia; Carboxymethylcellulose sodium, unspecified form
Dosage Form	Oral Tablet
Company	Recordati Rare Diseases
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Stearic acid	DIG Info	Phosphodiesterase 3A (IC50 = 3.1 uM)	[2]

References
1	FDA label for approved ethotoin from the official website of the U.S. Food and Drug Administration.
2	The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3	Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.